🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Bryan K. Kee

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0001-5553-2213
MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

(2023)10.1158/2767-9764.c.6975005.v1
Top 100%
0DataRank
Top 100%0 citations

Jane V. Thomas, Kaysia Ludford, Jason Willis, Victoria Serpas Higbie, Kanwal Raghav +15 more

Papers

Driven by 12 papers — median percentile 0. Top paper: “Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer”.

Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-in-Human Clinical Trial in Patients with Advanced Metastatic Cancer

Cancer Immunology Research(2023)10.1158/2326-6066.cir-22-0444
N/A
0.656DataRank · unranked
14 citations

Kerstin Guenther, Börje S. Andersson, Regina Mendrzyk, Amir Alpert, Claudia Wagner +36 more

PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers

ESMO Open(2021)10.1016/j.esmoop.2021.100230
N/A
0.564DataRank · unranked
42 citations

S. Greg Call, Helen J. Huang, A.L. Stuckett, Kiran Madwani, Abha Adat +16 more

Phase 1/2 trial of encorafenib, cetuximab, and nivolumab in microsatellite stable BRAFV600E metastatic colorectal cancer

Cancer Cell(2025)10.1016/j.ccell.2025.08.002
N/A
0.477DataRank · unranked
23 citations

Christine M. Parseghian, Vahid Bahrambeigi, Nourhan Abdelfattah, Lianchun Xiao, Anjali Agrawal +28 more

Phase I trial of single-photon emission computed tomography–guided liver-directed radiotherapy for patients with low functional liver volume

JNCI Cancer Spectrum(2024)10.1093/jncics/pkae037
N/A
0.340DataRank · unranked
6 citations

Franklin C. Wong, Beth Chasen, William D. Erwin, Prajnan Das, Emma B. Holliday +27 more

Clinical and pathologic features correlated with rare favorable survival in patients with BRAFV600E mutated colorectal cancer

Journal of Gastrointestinal Oncology(2022)10.21037/jgo-21-471
N/A
0.241DataRank · unranked
4 citations

Bryan K. Kee, Michael J. Overman, Arvind Dasari, Kanwal Raghav, Benny Johnson +6 more

Data from Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer

(2023)10.1158/2767-9764.c.6550830.v1
N/A
0DataRank · unranked
0 citations

Michael J. Overman, Michael Hon‐Wah Lam, Christine M. Parseghian, Benny Johnson, Arvind Dasari +17 more

Data from Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

(2023)10.1158/2767-9764.c.6975005.v1
Top 100%
0DataRank
Top 100%0 citations

Jane V. Thomas, Kaysia Ludford, Jason Willis, Victoria Serpas Higbie, Kanwal Raghav +15 more

Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal Cancer after Treatment Termination

Cancer Research Communications(2023)10.1158/2767-9764.crc-23-0340
N/A
0DataRank · unranked
15 citations

Jane V. Thomas, Kaysia Ludford, Jason Willis, Victoria Serpas Higbie, Kanwal Raghav +15 more

Phase II trial of bintrafusp alfa in patients with metastatic MSI-H cancers following progression on immunotherapy.

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.3_suppl.79
N/A
0DataRank · unranked
15 citations

Michael Lam, Xuemei Wang, Michael J. Overman, Benny Johnson, Bryan K. Kee +7 more

Phase 2 study of anti-EGFR rechallenge therapy with panitumumab with or without trametinib in advanced colorectal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3520
N/A
0DataRank · unranked
9 citations

Eduardo Vilar Sanchez, Ryan Sun, Madhulika Eluri, Van K. Morris, Benny Johnson +11 more

RAS co-mutation and early onset disease represent an aggressive phenotype of atypical (non-V600) BRAF mutant metastatic colorectal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.3592
N/A
0DataRank · unranked
0 citations

Dongyun Yang, Hiba I. Dada, Van K. Morris, Xuemei Wang, Arvind Dasari +14 more

Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin

UNC Libraries(2020)10.17615/kke1-de47
N/A
0DataRank · unranked
0 citations

Thomas LaFramboise, Michael S. Lee, Cathy Eng, David R. Fogelman, Stanley R. Hamilton +14 more